BCL2 and cancer: As a proof‐of‐concept study, antisense sequence (G3139) that targets BCL‐2 gene, a key regulatory gene to inhibit apoptosis of cancer cells,[27, 28] was selected and two PS modifications were introduced to the ASO sequence for drug grafting.